Korsana Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
quarter
View All ->Korsana Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Completed merger with Cyclerion Therapeutics and concurrent $380 million private placement Phase 1 healthy volunteer data for KRSA-028 expected mid-2027 and interim proof-of-concept data in Alzheimer’s disease patients anticipated by year-end 2027 or first quarter of 2028 Cash and cash equivalents of approximately $456.2 million as of September 30, 2026, expected to fund operations into 2029 WALTHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Korsana Biosciences, Inc. (“Korsana” or the “Company”)
Tenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Completed Statistical Analyses of LEVEL Yielded a Predictive Enrichment Strategy Being Applied in Amended LEVEL-2 Protocol Company Has Been Granted a Type C Meeting with the FDA CHAPEL HILL, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) today reported financial results for the quarter ended September 30, 2026 and provided an update on recent corporate progress. On August 10, 2026, Tenax announced that LEVEL, the
newsKorro Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Started dosing healthy volunteers with KRRO-121 in the Phase 1/2 clinical trial (ANCHOR) Expect to dose participants with Urea Cycle Disorders (UCDs) in the first half of 2027 Anticipate reporting interim data in the second half of 2027 Achieved best-in-class preclinical data with SERPINA1 mRNA editing (>95%) with KRRO-111 Planned regulatory submission in the first half of 2027 Ended third quarter 2026 with $124.8 million in cash, cash equivalents and marketable securities, supporting a cash run
results
View All ->Korsana Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Completed merger with Cyclerion Therapeutics and concurrent $380 million private placement Phase 1 healthy volunteer data for KRSA-028 expected mid-2027 and interim proof-of-concept data in Alzheimer’s disease patients anticipated by year-end 2027 or first quarter of 2028 Cash and cash equivalents of approximately $456.2 million as of September 30, 2026, expected to fund operations into 2029 WALTHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Korsana Biosciences, Inc. (“Korsana” or the “Company”)
Tenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Completed Statistical Analyses of LEVEL Yielded a Predictive Enrichment Strategy Being Applied in Amended LEVEL-2 Protocol Company Has Been Granted a Type C Meeting with the FDA CHAPEL HILL, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) today reported financial results for the quarter ended September 30, 2026 and provided an update on recent corporate progress. On August 10, 2026, Tenax announced that LEVEL, the
newsKorro Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Started dosing healthy volunteers with KRRO-121 in the Phase 1/2 clinical trial (ANCHOR) Expect to dose participants with Urea Cycle Disorders (UCDs) in the first half of 2027 Anticipate reporting interim data in the second half of 2027 Achieved best-in-class preclinical data with SERPINA1 mRNA editing (>95%) with KRRO-111 Planned regulatory submission in the first half of 2027 Ended third quarter 2026 with $124.8 million in cash, cash equivalents and marketable securities, supporting a cash run
third
View All ->Korsana Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Completed merger with Cyclerion Therapeutics and concurrent $380 million private placement Phase 1 healthy volunteer data for KRSA-028 expected mid-2027 and interim proof-of-concept data in Alzheimer’s disease patients anticipated by year-end 2027 or first quarter of 2028 Cash and cash equivalents of approximately $456.2 million as of September 30, 2026, expected to fund operations into 2029 WALTHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Korsana Biosciences, Inc. (“Korsana” or the “Company”)
Tenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Completed Statistical Analyses of LEVEL Yielded a Predictive Enrichment Strategy Being Applied in Amended LEVEL-2 Protocol Company Has Been Granted a Type C Meeting with the FDA CHAPEL HILL, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) today reported financial results for the quarter ended September 30, 2026 and provided an update on recent corporate progress. On August 10, 2026, Tenax announced that LEVEL, the
newsKorro Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Started dosing healthy volunteers with KRRO-121 in the Phase 1/2 clinical trial (ANCHOR) Expect to dose participants with Urea Cycle Disorders (UCDs) in the first half of 2027 Anticipate reporting interim data in the second half of 2027 Achieved best-in-class preclinical data with SERPINA1 mRNA editing (>95%) with KRRO-111 Planned regulatory submission in the first half of 2027 Ended third quarter 2026 with $124.8 million in cash, cash equivalents and marketable securities, supporting a cash run
reports
View All ->Korsana Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Completed merger with Cyclerion Therapeutics and concurrent $380 million private placement Phase 1 healthy volunteer data for KRSA-028 expected mid-2027 and interim proof-of-concept data in Alzheimer’s disease patients anticipated by year-end 2027 or first quarter of 2028 Cash and cash equivalents of approximately $456.2 million as of September 30, 2026, expected to fund operations into 2029 WALTHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Korsana Biosciences, Inc. (“Korsana” or the “Company”)
Tenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Completed Statistical Analyses of LEVEL Yielded a Predictive Enrichment Strategy Being Applied in Amended LEVEL-2 Protocol Company Has Been Granted a Type C Meeting with the FDA CHAPEL HILL, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) today reported financial results for the quarter ended September 30, 2026 and provided an update on recent corporate progress. On August 10, 2026, Tenax announced that LEVEL, the
newsKorro Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Started dosing healthy volunteers with KRRO-121 in the Phase 1/2 clinical trial (ANCHOR) Expect to dose participants with Urea Cycle Disorders (UCDs) in the first half of 2027 Anticipate reporting interim data in the second half of 2027 Achieved best-in-class preclinical data with SERPINA1 mRNA editing (>95%) with KRRO-111 Planned regulatory submission in the first half of 2027 Ended third quarter 2026 with $124.8 million in cash, cash equivalents and marketable securities, supporting a cash run
financial
View All ->Korsana Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Completed merger with Cyclerion Therapeutics and concurrent $380 million private placement Phase 1 healthy volunteer data for KRSA-028 expected mid-2027 and interim proof-of-concept data in Alzheimer’s disease patients anticipated by year-end 2027 or first quarter of 2028 Cash and cash equivalents of approximately $456.2 million as of September 30, 2026, expected to fund operations into 2029 WALTHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Korsana Biosciences, Inc. (“Korsana” or the “Company”)
Tenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Completed Statistical Analyses of LEVEL Yielded a Predictive Enrichment Strategy Being Applied in Amended LEVEL-2 Protocol Company Has Been Granted a Type C Meeting with the FDA CHAPEL HILL, N.C., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) today reported financial results for the quarter ended September 30, 2026 and provided an update on recent corporate progress. On August 10, 2026, Tenax announced that LEVEL, the
newsKorro Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Started dosing healthy volunteers with KRRO-121 in the Phase 1/2 clinical trial (ANCHOR) Expect to dose participants with Urea Cycle Disorders (UCDs) in the first half of 2027 Anticipate reporting interim data in the second half of 2027 Achieved best-in-class preclinical data with SERPINA1 mRNA editing (>95%) with KRRO-111 Planned regulatory submission in the first half of 2027 Ended third quarter 2026 with $124.8 million in cash, cash equivalents and marketable securities, supporting a cash run
Magazine Focus
The New Growth Playbook: Building Businesses for Sustainable Expansion
Growth is being redefined. Expanding revenue remains important, but businesses are placing greater emphasis on profitability, cash discipline, operational efficiency, customer retention and resilience. This edition explores the changing growth playbook and the foundations required for sustainable expansion. From technology and process design to capital allocation and market reach, it examines how businesses can pursue ambition without allowing complexity, costs or uncontrolled expansion to weaken the enterprise.
For years, growth was often discussed primarily in terms of size, speed and market share. The conversation is becoming more balanced. Strong businesses also need healthy economics, efficient operations and the ability to withstand uncertainty. This edition looks at growth through that wider lens and considers how organizations can expand with greater discipline, clarity and long-term purpose in practice.
The day in focus. Delivered to your inbox.
A concise daily briefing of key stories, insights and developments, selected by our editorial team.
By subscribing, you agree to our Privacy Policy. Unsubscribe at any time.